LAVA Therapeutics stock rises on acquisition deal with XOMA Royalty

Published 04/08/2025, 13:54
© Reuters.

Investing.com -- LAVA Therapeutics N.V. (NASDAQ:LVTX) stock rose 4.2% following the announcement of a definitive share purchase agreement with XOMA Royalty Corporation (NASDAQ:XOMA).

Under the terms of the agreement, XOMA Royalty will acquire LAVA for between $1.16 and $1.24 per share in cash, plus a non-transferable contingent value right (CVR) representing 75% of net proceeds from LAVA’s partnered assets and any out-licensing or sale of unpartnered programs.

The acquisition follows what LAVA described as a "thorough and wide-ranging strategic review process" aimed at maximizing shareholder value. LAVA’s Board of Directors unanimously approved the agreement and recommends shareholders support and accept the offer.

XOMA Royalty CEO Owen Hughes stated, "We believe the structure of this transaction has the potential to benefit both LAVA and XOMA Royalty shareholders over time. We are adding economics related to LAVA’s partnered programs investigating the utility of gamma delta bispecific antibodies, which hold significant promise for patients."

As part of the transaction, LAVA plans to discontinue its Phase 1 clinical trial of LAVA-1266 for acute myeloid leukemia and myelodysplastic syndrome and will wind down the program.

XOMA Royalty will commence a tender offer by August 15, 2025, with transaction closing expected in the fourth quarter of 2025. The offer requires tender of at least 80% of LAVA’s outstanding shares and approval at LAVA’s shareholders meeting, among other conditions.

Leerink Partners is acting as exclusive financial advisor to LAVA for the transaction.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.